Factors influencing the trailing endpoint observed in Candida albicans susceptibility testing using the CLSI procedure

Clinical Microbiology and Infection

Volumn 14, Issue 5, 2008, Pages 495-497

  Coenye, Tom ^a   De Vos, M ^a   Vandenbosch, D ^a   Nelis, H ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Candida albicans; CLSI method; EUCAST method; Fluconazole; Susceptibility testing; Trailing endpoint

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GLUCOSE; PYRROLE DERIVATIVE;

ANALYTIC METHOD; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FUNGUS GROWTH; FUNGUS ISOLATION; INCIDENCE; INTERMETHOD COMPARISON; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

CANDIDA ALBICANS;

EID: 41949125970     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.01956.x     Document Type: Article

References (12)

1. Rex JH, Pfaller MA, Walsh TJ et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643-658.
2. National Committee for Clinical laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts, M27-A2. Wayne, PA: NCCLS, 2002.
3. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST Definitive Document E Def 7.1: Method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008; 14: 398-405.
4. Rodriguez-Tudela JL, Donnelly JP, Pfaller MA et al. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol 2007; 45: 109-111.
5. Cuenca-Estrella M, Lee-Yang W, Ciblak MA et al. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob Agents Chemother 2002; 46: 3644-3647.
6. Revankar SG, Kirkpatrick WR, McAtee RK et al. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol 1998; 36: 153-156.
7. Arthington-Skaggs BA, Lee-Yang W, Ciblak MA et al. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in.vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother 2002; 46: 2477-2481.
8. Arthington-Skaggs BA, Warnock DW, Morrison CJ. Quantitation of Candida albicans ergosterol content improves the correlation between in.vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob Agents Chemother 2000; 44: 2081-2085.
9. Marr KA, Rustad TR, Rex JH et al. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob Agents Chemother 1999; 43: 1383-1386.
10. Cuenca-Estrella M, Diaz-Guerra TM, Mellado E et al. Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp. J Clin Microbiol 2001; 39: 525-532.
11. Agrawal D, Patterson TF, Rinaldi MG et al. Trailing end-point phenotype of Candida spp. in antifungal susceptibility testing to fluconazole is eliminated by altering incubation temperature. J Med Microbiol 2007; 56: 1003-1004.
12. Lee MK, Williams LE, Warnock DW et al. Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother 2004; 53: 217-224.